Diseases [C] » Eye Diseases [C11] » Retinal Diseases
Hierarchy View
Subtype Terms (22)
Angioid Streaks
4 approved drugs
Central Serous Chorioretinopathy
29 drugs (23 approved, 6 experimental)
Diabetic Retinopathy
139 drugs (64 approved, 75 experimental)
Epiretinal Membrane
20 drugs (14 approved, 6 experimental)
Familial Exudative Vitreoretinopathies
1 approved drug
Leber Congenital Amaurosis
12 drugs (6 approved, 6 experimental)
Retinal Artery Occlusion
6 drugs (5 approved, 1 experimental)
Retinal Degeneration
24 drugs (7 approved, 17 experimental)
Retinal Detachment
31 drugs (23 approved, 8 experimental)
Retinal Hemorrhage
3 approved drugs
Retinal Neoplasms
8 approved drugs
Retinal Neovascularization
6 drugs (3 approved, 3 experimental)
Retinal Perforations
12 drugs (9 approved, 3 experimental)
Retinal Telangiectasis
4 drugs (2 approved, 2 experimental)
Retinal Vasculitis
4 approved drugs
Retinal Vein Occlusion
44 drugs (28 approved, 16 experimental)
Retinitis
3 experimental drugs
Retinopathy of Prematurity
40 drugs (23 approved, 17 experimental)
Vitreoretinopathy, Proliferative
20 drugs (17 approved, 3 experimental)
Approved Indicated Drugs (2)
Phase 4 Indicated Drugs (18)
Phase 2 Indicated Drugs (17)
Phase 1 Indicated Drugs (10)
Other Experimental Indicated Drugs (13)
Organization Involved with Phase 4 Indications (48)
King Khaled Eye Specialist Hospital
National Institute for Health Research, United Kingdom
NHS Scotland Diabetic Retinopathy Screening Collaborative
Organization Involved with Phase 3 Indications (90)
Asociación para Evitar la Ceguera en México
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
Case Western Reserve University
Centre Hospitalier Intercommunal Creteil
Charlotte Eye Ear Nose and Throat Assciates, PA
Cyril and Methodius University
European Vision Institute Clinical Research Network
Hannover Clinical Trial Center GmbH
Huazhong University of Science and Technology
Instituto Mexicano del Seguro Social
Institut Universitaire de Recherche Clinique, RD Nephrologie SAS
Jaeb Center for Health Research
Juvenile Diabetes Research Foundation
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Child Health and Human Development (NICHD)
Ophthalmic Consultants of Long Island
Ospedale Maggiore San Giovanni Bosco
Pan American Collaborative Retina Study Group
Queen Silvia Children's Hospital, Gothenburg, Sweden
Retina Associates, Kansas City
Shahid Beheshti University of Medical Sciences
Steno Diabetes Center Copenhagen
The University of Texas, Dallas
Universidad Autonoma de Madrid
University of Alabama, Birmingham
Organization Involved with Phase 2 Indications (75)
Chengdu University of Traditional Chinese Medicines
Chongqing Taiji Group of Fuling pharmaceutical Co., LTD
Eye Center of Northern Colorado
Guangdong Women and Children Hospital
Instituto Mexicano de Oftalmologia
Memorial Sloan-Kettering Cancer Center
National Autonomous University of Mexico
National Health and Medical Research Council, Australia
Oncology Service, Wills Eye Institute
Ophthalmic Consultants of Boston
Pediatric Eye Disease Investigator Group
Retina Specialists of Michigan
Rocky Mountain Retina Consultants
Rubens Siqueira Research Center
Schepens Eye Research Institute
Semler Research Center Pvt. Ltd.
Organization Involved with Phase 1 Indications (42)
Anhui College of Traditional Chinese Medicine
Baodin City Hospital of Traditional Chinese Medicine
China Academy of Chinese Medical Sciences
Fountain Medical Development Co., Ltd.
Hubei University of Chinese Medicine
King Faisal Specialist Hospital
Manhattan Eye, Ear & Throat Hospital
Medicine Zibo Wanjie Tumor Hospital
Organization Involved with Other Experimental Indications (28)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.